Biocon Biologics, a subsidiary of biotechnology major Biocon Ltd, has secured its board’s approval for an investment of $150 million (Rs 1,125 crore) from US-based investment bank Goldman Sachs.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
